Therapeutic Management of Primary Immunodeficiency in Older Patients

被引:10
作者
Verma, Nisha [1 ,2 ]
Thaventhiran, Anthony [1 ,2 ]
Gathmann, Benjamin [3 ,4 ]
Thaventhiran, James [1 ,2 ]
Grimbacher, Bodo [1 ,2 ,3 ,4 ]
机构
[1] Royal Free Hosp, Dept Immunol & Mol Pathol, London NW3 2QG, England
[2] UCL, London, England
[3] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany
[4] Univ Freiburg, D-79106 Freiburg, Germany
关键词
COMMON VARIABLE IMMUNODEFICIENCY; X-LINKED AGAMMAGLOBULINEMIA; PRIMARY ANTIBODY DEFICIENCY; STEM-CELL TRANSPLANTATION; INTRAVENOUS IMMUNOGLOBULIN; PRIMARY HYPOGAMMAGLOBULINEMIA; LYMPHOID-TISSUE; LARGE COHORT; EFFICACY; DISEASE;
D O I
10.1007/s40266-013-0079-7
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Primary immunodeficiency disease (PID) has traditionally been viewed as a group of illnesses seen in the paediatric age group. New advances in diagnosis and treatment have led to an increase in the number of elderly PID patients. However, there is lack of research evidence on which to base clinical management in this group of patients. Management decisions often have to be based therefore on extrapolations from other patient cohorts or from younger patients. Data from the European Society for Immunodeficiencies demonstrates that the vast majority of elderly patients suffer from predominantly antibody deficiency syndromes. We review the management of PID disease in the elderly, with a focus on antibody deficiency disease.
引用
收藏
页码:503 / 512
页数:10
相关论文
共 56 条
  • [1] Lymphoma of mucosa-associated lymphoid tissue in common variable immunodeficiency
    Aghamohammadi, A
    Parvaneh, N
    Tirgari, F
    Mahjoob, F
    Movahedi, M
    Gharagozlou, M
    Mansouri, M
    Kouhi, A
    Rezaei, N
    Webster, D
    [J]. LEUKEMIA & LYMPHOMA, 2006, 47 (02) : 343 - 346
  • [2] Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity?
    Alcais, Alexandre
    Quintana-Murci, Lluis
    Thaler, David S.
    Schurr, Erwin
    Abel, Laurent
    Casanova, Jean-Laurent
    [J]. YEAR IN HUMAN AND MEDICAL GENETICS: NEW TRENDS IN MENDELIAN GENETICS, 2010, 1214 : 18 - 33
  • [3] [Anonymous], 1999, CLIN EXP IMMUNOL S1, VIII, P1
  • [4] Practice parameter for the diagnosis and management of primary immunodeficiency
    Bonilla, FA
    Bernstein, IL
    Khan, DA
    Ballas, ZK
    Chinen, J
    Frank, MM
    Kobrynski, LJ
    Levinson, AI
    Mazer, B
    Nelson, RP
    Orange, JS
    Routes, JM
    Shearer, WT
    Sorensen, RU
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2005, 94 (05) : S1 - S63
  • [5] BRUTON OC, 1952, PEDIATRICS, V9, P722
  • [6] Safety of intravenous immunoglobulin treatment
    Caress, James B.
    Kennedy, Burton L.
    Eickman, Kara D.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2010, 9 (06) : 971 - 979
  • [7] Case-control study of thromboembolic events associated with IV immunoglobulin
    Caress, James B.
    Hobson-Webb, Lisa
    Passmore, Leah V.
    Finkbiner, Anne P.
    Cartwright, Michael S.
    [J]. JOURNAL OF NEUROLOGY, 2009, 256 (03) : 339 - 342
  • [8] The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy
    Chapel, HM
    Spickett, GP
    Ericson, D
    Engl, W
    Eibl, MM
    Bjorkander, J
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2000, 20 (02) : 94 - 100
  • [9] Special Considerations with the Use of Intravenous Immunoglobulin in Older Persons
    Cheng, M. Jennifer
    Christmas, Colleen
    [J]. DRUGS & AGING, 2011, 28 (09) : 729 - 736
  • [10] Diagnostic criteria for primary immunodeficiencies
    Conley, ME
    Notarangelo, LD
    Etzioni, A
    [J]. CLINICAL IMMUNOLOGY, 1999, 93 (03) : 190 - 197